No Data
No Data
Zhongzhi: Expect Lower Profit Due to Decline in Gross Profit Margin, Higher Investment Costs
Zhongzhipharm (03737.HK): Expects a year-on-year decline of around 40% in net profit for the first half of the year.
Zhongzhipharm (03737.HK) announced that based on the preliminary review of the unaudited comprehensive management accounts of the Group as of June 30, 2024, it is expected that the net profit for the six months ending June 30, 2024 will decrease by about 40% compared to the six months ending June 30, 2023. The expected decrease in net profit is mainly due to: (i) changes in sales product structure leading to a decrease in gross margin; (ii) increased investment in online channels.
Express News | Zhongzhi Pharmaceutical Sees Decrease in Gross Profit Margin for Hy
Express News | Zhongzhi Pharmaceutical Sees Decrease in Net Profit of Around 40% for Hy
ZHONGZHIPHARM: PROFIT WARNING
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
No Data